A collaborative study from City of Hope and UC Berkeley unveils MechanoAge, a microfluidic platform that assesses individual breast cancer risk by analyzing the mechanical aging of single breast epithelial cells.

The researchers note that many women lack known genetic risk despite cancer incidence, and existing density-based or population-model estimates can misclassify risk, potentially leading to over- or under-screening.

The Lancet eBioMedicine paper details a machine-learning pipeline that differentiates mechanical properties and assigns a numerical risk score, and it acknowledges there is currently no widely available non-genetic test for identifying women at higher risk.

MechanoAge is built on a scalable, affordable setup using simple electronics and computer chips, avoiding expensive imaging tech used in prior methods.

The device leverages mechano-node-pore sensing with a straightforward hardware design to capture mechanical cell properties, enabling scalable risk assessment without costly imaging equipment.

Researchers emphasize that MechanoAge could be highly scalable and affordable, making non-genetic risk assessment more accessible and enabling earlier, personalized clinician discussions.

From the researchers’ perspective, MechanoAge can provide tangible, cell-derived risk information for patients to discuss with doctors, with scalability rooted in its simple hardware.

Funding comes from NIH and the American Cancer Society, with no competing interests reported; related patent activity suggests groundwork for commercialization.

Validation across diverse cohorts shows accuracy in distinguishing high-risk profiles and aligning risk scores with genetic susceptibility and clinical diagnoses.

The platform can identify high-risk individuals, including those with known genetic mutations, and distinguish them from healthy controls and people with non-genetic risk factors.

Looking ahead, MechanoAge could enable earlier, more precise cellular-level breast cancer risk detection, broader accessibility, and potential applications to other age-related diseases.

MechanoAge uses mechano-node-pore sensing to monitor cell translocation and real-time data on size, shape, deformability, and recovery dynamics, yielding an integrated health and resilience index.